If I were a professional investor, I might start investing in GLP-1 agonist drugs. But I’m not an investor, just a doctor. So I’d tell you that with the usual caveats, the early news about glucagon-like peptides in treating addictions is simply fascinating.
Ozempic to curb alcoholism, or drug use? A diabetes medication that can help you quit cigarettes? It sounds too good to be true. And some of it may be.
We don’t want another thalidomide disaster on our hands.
But if even a little of it is true, and no serious harm emerges over time, it would be huge. Hugely beneficial for patients stuggling with obesity (and the diseases that stem from overweight/obesity, like many cases of diabetes, heart disease, strokes, and even some cancers) and a wide range of addictions and substance abuse disorders.